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Abstract—A link between oral health and cardiovascular disease has been proposed for more than a century. Recently,
concern about possible links between periodontal disease (PD) and atherosclerotic vascular disease (ASVD) has
intensified and is driving an active field of investigation into possible association and causality. The 2 disorders share
several common risk factors, including cigarette smoking, age, and diabetes mellitus. Patients and providers are
increasingly presented with claims that PD treatment strategies offer ASVD protection; these claims are often endorsed
by professional and industrial stakeholders. The focus of this review is to assess whether available data support an
independent association between ASVD and PD and whether PD treatment might modify ASVD risks or outcomes. It
also presents mechanistic details of both PD and ASVD relevant to this topic. The correlation of PD with ASVD
outcomes and surrogate markers is discussed, as well as the correlation of response to PD therapy with ASVD event
rates. Methodological issues that complicate studies of this association are outlined, with an emphasis on the terms and
metrics that would be applicable in future studies. Observational studies to date support an association between PD and
ASVD independent of known confounders. They do not, however, support a causative relationship. Although
periodontal interventions result in a reduction in systemic inflammation and endothelial dysfunction in short-term
studies, there is no evidence that they prevent ASVD or modify its outcomes. (Circulation. 2012;125:2520-2544.)
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Well over a century ago, oral sepsis and dental extrac-tions were proposed as causes of infection of cardiac
tissues (ie, infective endocarditis).1 This focal infection the-
ory evolved over the following half century to become part of
a larger concern about the linkage of focal odontogenic
infection and a long list of diverse medical conditions remote
from the mouth. An unprecedented surge in dental extractions
ensued over several decades.2–6 By the mid-20th century, lack
of supporting scientific evidence tempered the focus on oral
disease as a cause of systemic illness. That focus was revived
20 years ago after reports of a potential connection between
chronic periodontal diseases (PDs) and atherosclerotic vascular
disease (ASVD).7,8 A dramatic increase in publications on this
topic followed in 190 different journals (Figure 1).
Although many subsequent studies have suggested positive
associations between these 2 diseases, others have not,
particularly after adjustment for potential confounding vari-
ables.9 At the same time, several potential mechanisms by
which PD could cause systemic inflammation, promote
atherogenesis, or incite cardiovascular catastrophes such as
myocardial infarction (MI) or stroke have been proposed.
Whether an independent, clinically significant association
exists between the 2 disorders remains controversial.
This question has tremendous importance given the high
incidences of both diseases, their economic costs to society,
and the potential impact on public health if risk modification
or therapeutic opportunities could be identified. The lack of
consensus among experts and the confusion among health-
care providers and the public all suggest the need for a
systematic review of the topic. Therefore, the present docu-
ment was prepared to review the relevant pathophysiology,
predominant theories, and investigative approaches and to
assess the quality of available data that characterize the topic.
Methods
The American Heart Association’s Committee on Rheumatic
Fever, Endocarditis, and Kawasaki Disease, which includes
representatives from dental, infectious diseases, cardiology, and
epidemiology communities, convened a writing group charged
with assessing the weight and scope of evidence for an associ-
ation or causality of PD and ASVD.
From May 2008 to July 2011, we conducted a series of
literature searches in the database Ovid MEDLINE In-Process &
Other Nonindexed Citations and Ovid MEDLINE for English-
language articles on the association between PD and any
cerebrovascular, peripheral vascular, or cardiovascular disease,
excluding infective endocarditis, Behc¸et syndrome, Stevens-
Johnson syndrome, and Sjo¨gren syndrome. The search strategy
included a combination of Medical Subject Headings and key
words (Table 1). The search covered the period of 1950 to July
2011 and included clinical studies, systematic reviews, animal
studies, and articles of material importance to the subject of this
report. Comments and letters, editorials, case reports, news
items, and consumer health material were excluded.
The search produced 473 articles that met inclusion crite-
ria. In addition, we identified 64 additional publications that
met inclusion criteria from the reference lists of these 473
articles, for a total of 537 peer-reviewed publications. The
majority appeared in the periodontal literature and other
dental journals (61%) compared with the medical literature
(39%). After review by writing group members for study
design, relevance, and quality, only those specifically dis-
cussed in the present report were referenced.
Definitions and Prevalence of Cardiovascular
Disease and PD
Cardiovascular Disease
ASVDs affect the heart and the blood vessels. Their major
components, defined as diseases of the circulatory system by
the International Classification of Diseases, 9th Revision, are
as follows: (1) Ischemic heart disease, (2) cerebrovascular
diseases, and (3) diseases of arteries, arterioles, and capillar-
ies (also known as peripheral vascular disease). ASVD is a
chronic process, with a progressive course over many years,
but it can cause acute clinical events, including acute coro-
nary syndromes (ACS), MI, and stroke.
Figure 1. Periodontal/cardiovascular disease articles. The num-
ber of new peer-reviewed publications in English language jour-
nals on the topic of periodontal disease and all types of cardio-
vascular, peripheral vascular, and cerebrovascular diseases for
3-year periods is shown from 1989 (when the first article
appeared) through 2010.
Table 1. Search Strategy and Criteria
The basic search strategy in Ovid MEDLINE In-Process & Other Non-indexed
Citations and Ovid MEDLINE was as follows:
Database: Ovid MEDLINE In-Process & Other Non-Indexed Citations and Ovid
MEDLINE 1950 through July 31, 2011
Search strategy:
1. exp Periodontal diseases/
2. exp Cerebrovascular disorders/
3. exp Cardiovascular diseases/
4. exp Cardiovascular system/
5. exp Periodontium/
6. exp Periodontics/
7. (1 or 5 or 6) and (2 or 3 or 4)
8. limit 7 to English language
9. limit 8 to (comment or letter or news or newspaper article)
10. 8 not 9
11. (periodont$ or tooth or teeth or gingiv$ or furcat$ or pericoroni$ or
periapical or alveolar).af.
12. limit 11 to in process
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Atherosclerotic vascular diseases are the number 1 cause of
death globally, accounting for30% of all deaths worldwide. In
the United States, despite declining trends in ASVD mortality
since the early 1980s, ASVD remains the leading cause of
disability and mortality, accounting for 1 in 3 deaths.10
The most common form of ASVD in the United States is
ischemic heart disease, which caused more than half of all
ASVD deaths in 2008.10 Each year, an estimated 785 000
Americans have a new coronary event, and 470 000 experi-
ence a recurrent attack. It is estimated that an additional 195 000
silent first MIs occur annually. Additional ASVD burden pres-
ents as stroke: Each year,795 000 people experience a new or
recurrent stroke, and final data from 2008 indicate that stroke
accounted for 1 of every 18 deaths in the United States.10
Lower extremity peripheral artery disease, one of the most
common manifestation of peripheral vascular disease, is esti-
mated to affect 12% to 20% of the US population 65 years of
age and 8 million Americans.10 Overall, the spectrum of
ASVD imposes a substantial cost to society. The total estimated
direct and indirect costs of ASVD, including stroke, in the
United States exceeded $298 billion in 2008.10 A review of the
pathophysiology of ASVD is beyond the scope of the present
report.
Periodontal Disease
Periodontal diseases comprise a continuum of conditions involv-
ing inflammation of gingival tissues in response to dental plaque
accumulation (Figure 2). These conditions may present with
(“periodontitis”) or without (“gingivitis”) substantial inflamma-
tory destruction of the supporting tissues, including gingival
tissue, periodontal ligament, and alveolar bone.
Assessment of the global prevalence of PD across different
populations has been impacted by substantial variation in the
clinical criteria, such as bleeding on probing, pocket depth, and
degree of attachment loss used to define the presence and
severity of PD among studies. Grading systems for use in
epidemiological studies have been proposed but have not been
applied consistently. A lack of consensus on how to incorporate
tooth loss data in prevalence estimates is an especially important
limitation in elderly cohorts, because loss may occur because of
dental disorders other than PD.11
A recent review of the epidemiological patterns of periodon-
titis reported a range in prevalence of severe periodontitis from
1% among 20- to 29-year-olds to 39% among individuals 65
years of age. Moderate forms of the disease were significantly
more common in all populations.12 On the basis of National
Health and Nutrition Examination Survey 1999–2004 data, the
prevalence of moderate to severe PD in the United States was
5% among those aged 35 to 49 years, 11% among those aged 50
to 64 years, 14% among those aged 65 to 74 years, and 20%
among those aged 75 years.13 The combined expenditure for
periodontal and preventive dental services in the United States
was estimated at $14.3 billion in 1999, whereas approximately
$4.4 billion was spent for periodontal procedures.14
Periodontal Disease
Basic Periodontal Anatomy
Teeth are supported by a connective tissue attachment appa-
ratus (periodontal ligament) that is partly inserted into the
outer layer of the root surface (root cementum) and partly into
bone of the maxillary or mandibular alveolar processes, and
to a lesser extent by gingival tissues that surround the teeth
(Figure 2). In states of periodontal health, the gingiva are firmly
attached to the root surface at the level of the junction between
tooth enamel and the root cementum. The highest level of the
gingival margin is located between 1 and 3 mm coronal to the
point where the gingiva attach to the tooth surface, which results
in a shallow space around the periphery of the tooth called the
gingival sulcus. Teeth and gingival epithelium that surround
teeth form several different ecological environments, each suit-
able for colonization by a distinct group of microorganisms. The
gingival sulcus is a unique ecological niche that is readily
colonized by oral bacteria that form a biofilm, or dental plaque.
Pathophysiology
In periodontitis, bacterially induced inflammatory processes
result in deepening of the gingival sulcus, which evolves into a
Figure 2. Periodontal anatomy in health
and disease. Molar tooth with periodon-
tal anatomy in health (left side) and with
periodontal disease (right side). Note
the greatly increased depth of the 1- to
2-mm gingival sulcus caused by loss of
the gingival attachment to create a peri-
odontal pocket of 5 mm; the inflamed
and swollen gingival papilla and the loss
of alveolar bone from the inflammatory
response from subgingival plaque and
calculus; and the presence of ulceration
of the periodontal pocket mucosa and
resultant loss of a mucosal barrier
between the plaque bacteria and the
increased gingival circulation. Courtesy
of Anne Olson.
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periodontal pocket; apical migration of both the gingival attach-
ment to the root surface and plaque biofilm; loss of connective
tissue attachment and alveolar bone; and gingival recession.
Three clinical parameters are typically recorded in epidemio-
logical studies of PD to assess prevalence: (1) Bleeding on
probing, which reflects the presence of an inflammatory infil-
trate in gingival tissues with loss of integrity of the sulcular
epithelium; (2) pocket depth, which describes the deepening of
the gingival sulcus from which dental plaque biofilm can
propagate apically along the root surface; and (3) clinical
attachment level, which reflects the amount of periodontal tissue
loss. Thus, bleeding on probing and increased pocket depth are
more indicative of current pathology, whereas attachment levels
provide a cumulative measure of loss of support caused by the
aggregate effects of pathogenetic factors such as PD and trauma.
Clinical data are usually summarized as mean values of the
above parameters or as measures of extent (ie, the percentage of
sites in dentition that are affected by bleeding on probing,
pocketing, or attachment loss) and severity (ie, the magnitude of
loss of tissue support caused by disease, expressed in millimeters).
Other markers of periodontitis include evaluations of subgin-
gival microbial colonization by selected periodontal organ-
isms15–18 and levels of serum IgG or IgA antibodies to selected
periodontal bacteria.19–26 A positive correlation between extent
and severity of PD and increased levels of colonization by
specific microbial species is widely accepted27,28; in contrast, the
association between periodontal pathology and elevated anti-
body titers to putative pathogens is highly variable.29 In some
cases, high titers likely suggest the presence of a protective
adaptive response, whereas in others, they reflect the severity of
periodontitis.30 This complicates the interpretation of data from
studies that have exclusively used serological markers of perio-
dontitis to study the association between periodontal infections
and ASVD.
Microbiology of PD
A newly cleaned tooth surface is rapidly covered with a
glycoprotein deposit referred to as a pellicle. The pellicle is
derived from salivary constituents that are selectively adsorbed
onto hydroxyapatite of the tooth surface. Microorganisms in-
habit the pellicle above and below the gingival margin as
supragingival and subgingival plaque. Unlike other bacterial
ecosystems that inhabit continuously shedding epithelial sur-
faces, dental plaque develops on the nonshedding surface of
teeth. It is a biofilm that consists of a complex microbial
community embedded in a matrix of polymers of bacterial and
salivary origin. The supragingival plaque is bathed by saliva, and
the subgingival plaque is bathed by transudative fluid in the
gingival sulcus.31 In the presence of periodontitis, plaque in the
periodontal pocket is bathed by exudative fluid, blood, or both.
The microbial composition of dental plaque differs above and
below the gingival margin. Factors that influence the distinct
pattern of microflora that inhabit each anatomic site include
specific local surface receptors for bacterial adherence, oxygen
tension, redox potential, pH, microbial coaggregation, and microbial
interference. Microbial composition also varies by age, hormonal
changes, diet, oral hygiene, and presence of caries and PD.
Initial (“primary”) supragingival colonizers have particular
affinity for constituents of the pellicle. These colonizers
include Streptococcus sanguis, Streptococcus oralis, Strepto-
coccus mutans, Actinomyces naeslundii, and Actinomyces
odontolyticus. They provide attachment sites for interspecies
adherence, supply substrates required for growth of other
bacteria, and reduce oxygen tension to low levels that allow
growth and survival of obligate anaerobes. The primary
colonizers are followed by adherence of secondary coloniz-
ers, such as Fusobacterium nucleatum, which in turn coag-
gregate with later colonizers. Within a relatively short time,
complex communities of gram-positive and gram-negative
bacilli and cocci become embedded in an extracellular poly-
mer matrix.32 More than 500 distinct microbial species can be
recovered from dental plaque (Table 2).33 Bacterial counts above
the gingival margin on a single tooth surface can exceed 109
bacteria per gram.34 Below the gingival margin, the number of
bacteria ranges from 103 in a healthy, shallow sulcus to108 in
Table 2. Bacteriology of Dental Plaque
Facultative Anaerobic
Gram-positive cocci Streptococcus sanguis
Streptococcus oralis
Streptococcus mutans
Gram-positive bacilli Actinomyces naeslundii
Actinomyces odontolyticus
Actinomyces viscosus
Gram-negative cocci Neisseria species Veillonella species
Gram-negative bacilli Aggregatibacter (formerly Actinobacillus)
actinomycetemcomitans
Capnocytophaga species
Eikenella corrodens
Helicobacter pylori
Chlamydophila pneumoniae
Porphyromonas gingivalis
Fusobacterium nucleatum
Prevotella intermedia
Tannerella forsythia
Selenomonas noxia
Campylobacter rectus
Spirochetes Treponema denticola
Other Treponema species
Methanogenic archaea Methanobrevibacter oralis-like
Sulfate-reducing bacteria and archaea Desulfomicrobium orale
Desulfovibrio
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a periodontal pocket.35 Many of the microorganisms found in
subgingival plaque do not grow in culture.36
In healthy mouths, the most common organisms detected in
subgingival plaque include A naeslundii, S sanguis, S oralis,
Veillonella parvula, A odontolyticus, and F nucleatum.33,37 In
the presence of gingivitis, gram-negative microaerophilic
bacilli and gram-negative anaerobic bacilli predominate in
the subgingival flora. Subgingival microflora in gingivitis
represent a transition between that associated with health and
periodontitis,38 in which subgingival microflora shifts from
being predominately gram-positive to an increased number of
obligate anaerobic gram-negative organisms, such as Porphy-
romonas gingivalis, Tannerella forsythia, Treponema denticola,
and Selenomonas noxia, as well as Campylobacter rectus,
Aggregatibacter (formerly Actinobacillus) actinomycetemcomi-
tans, and Prevotella intermedia, and spirochetes.35–41 Other
microorganisms found in PD include Chlamydophila pneu-
moniae42; Mycoplasma43,44; Helicobacter pylori45–47; candida48–51;
Epstein-Barr virus, cytomegalovirus, and herpesviruses52–54;
ameba55; methane-producing microorganisms called archaea56–59;
and sulfate-reducing bacteria and archaea.60,61
Epithelium in the gingival sulcus interacts with bacteria in
the subgingival crevicular space, generating and transmitting
signals between bacteria and adjacent immune cells.62 This
results in elaboration of proinflammatory cytokines and chemo-
kines that are responsible for recruiting cells involved in innate
and acquired immune response and the inflammatory process
(dendritic cells, T and B cells, macrophages, and neutrophils).63
Several putative PD pathogens (P gingivalis, A actinomy-
cetemcomitans, and P intermedia) attach to gingival epithelial
cells and induce formation of membrane invaginations
(receptor-mediated endocytosis), which surround and engulf
bacteria.64–66 Survival and multiplication of intracellular P
gingivalis permits evasion of the immune system and possible
dissemination via the bloodstream.67
Risk Factors for PD and
Cardiovascular Disease
Risk factors associated with the development of PD include
local, systemic, and genetic factors. Although several bacterial
species are currently recognized as causally associated with
periodontitis,27 mere colonization of the subgingival niche by
these species is not sufficient for disease to occur.68 Instead, PD
is thought to evolve from the stage of gingivitis, that is, a local
inflammatory process without concomitant loss of periodontal
tissue support that likely represents a stable, largely protective
host response to periodontitis, an environment characterized by
loss of connective tissue attachment and alveolar bone, influ-
enced by detrimental environmental exposures and specific
genetic predispositions that are likely important determinants of
susceptibility.11,69 These include poor oral hygiene; cigarette
smoking; systemic conditions such as diabetes mellitus, osteo-
porosis, rheumatoid arthritis, and possibly obesity; and stress and
poor coping behaviors.69 In addition, a number of genetic
polymorphisms have been variably associated with propensity
for periodontitis and ASVD.70
Contributors to ASVD are similarly multifactorial and
include a complex interplay between genetic, environmental,
and lifestyle factors. The associated risk factors include those
that cannot be changed, such as ethnicity, age, and family
history of ASVD, and those that can be modified or con-
trolled, including dyslipidemia, hypertension, tobacco smoke,
excess body weight, physical inactivity, and diabetes melli-
tus. The role of these classic risk factors and their interaction
with cellular and noncellular mechanisms in the slow process
of atheromatous plaque development is clearly established,
with unequivocal evidence that by intervening on these risk
factors, one can impede or prevent the atherosclerotic process
and its clinical manifestations. In addition to factors associated
with long-term progression of atherosclerosis, including chronic
inflammation, there are also “triggering factors” that are more
acute and include increased inflammation and a cascade of
hemostasis and thrombosis. These triggers may lead to athero-
sclerotic plaque rupture and thrombosis, resulting in vessel
occlusion and acute clinical catastrophes such as MI or stroke.
Many prevalent risk factors with well-documented impact
are shared by ASVD and PD and could confound a relation-
ship between them. Increasing age, smoking, alcohol abuse,
race/ethnicity, education and socioeconomic status, male sex,
diabetes mellitus, and overweight or obesity are all factors
associated with both ASVD and PD.71,72
The presence of potentially significant confounding effects is
an important potential limitation in many studies because of the
nature of their study design (observational studies).73 A number
of studies, although not the majority of them, have presented
evidence that confounding factors could play a role in explain-
ing, at least in part, the observed association between ASVD and
PD. These factors include smoking and other lifestyle factors,
ASVD risk factors, age, and education and other social indica-
tors.73–78 The role of smoking in the observed association
between PD and cardiovascular disease outcomes is a critical
one because smoking can play a role both as a confounder and
as an effect modifier. Smoking is a major risk factor for both
periodontal and cardiovascular disease, and smoking cessation is
a critical component of health maintenance and prevention of
many diseases, including ASVD and PD. Statistical adjustment
for smoking in studies of the association between PD and ASVD
does not preclude the possibility for residual confounding;
however, recent evidence seems to indicate that the observed
association between PD and ASVD may be independent of
smoking. It has been shown, both in cross-sectional79 and in
longitudinal studies,80,81 that PD and ASVD are associated in
never-smokers as well.
Pathogenic Mechanisms Proposed as Links
Between Cardiovascular Disease and PD
Several pathophysiological pathways have been proposed as
potential links between PD and ASVD. These pathways
involve both direct and indirect interactions between peri-
odontal pathogens and the endothelium or other mechanisms
that impact the atherosclerotic process.
Indirect Mechanisms: Systemic Inflammation
Atherosclerosis may begin during childhood, with initial
infiltration of the endothelium with fatty substances, and
progresses over many decades. Chronic, quiescent atheroma-
tous plaque can transition to a more dangerous state in which
its vulnerability to rupture is increased. Plaques that contain a
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soft atheromatous core are unstable, and their rupture will
expose highly thrombogenic contents to blood, with activa-
tion of thrombosis and ensuing ACS, MI, or stroke.82 Major
determinants of increased plaque vulnerability are size and
consistency of the atheromatous core and both thinning and
inflammation of the fibrous cap covering the core. Such
inflammation manifests as infiltrates of monocytes/macro-
phages, T cells, and neutrophils within the cap tissues,82 as
well as by increased circulating markers of inflammation in
the blood. The link between ASVD and inflammatory medi-
ators in blood is well established, with consistent associations
between levels of systemic inflammatory markers and in-
creases in clinical events such as MI and nonhemorrhagic
stroke, and in surrogate markers such as increased carotid
intima-media thickness (cIMT).83
Systemic inflammation can be measured with several
inflammatory markers. A well-studied inflammatory marker
is C-reactive protein (CRP). More than a dozen prospective
epidemiological studies of individuals with no prior history of
ASVD have demonstrated that a single nonfasting measure of
CRP is a predictor of future vascular events, including MI,
stroke, peripheral arterial disease, and sudden cardiac death.84
CRP is an independent predictor of future cardiovascular events
that may add prognostic information to lipid screening, the
metabolic syndrome, and the Framingham risk score.85,86
Additional inflammatory markers associated with cardiovas-
cular disease include lipoprotein-associated phospholipase A2,87
matrix metalloproteinases and tissue inhibitors of matrix metal-
loproteinase,88 myeloperoxidase,89 and fibrinogen.90,91 Other
inflammatory markers (eg, interleukin 6 [IL-6], soluble intercellular
adhesion molecule-1, macrophage inhibitory cytokine-1, and solu-
ble CD40 ligand) have been shown to be elevated among those at
increased vascular risk, albeit to a lesser magnitude than CRP.85
Periodontal inflammation is similarly associated with in-
creased systemic inflammatory markers, including CRP, tumor
necrosis factor-, IL-1, IL-6, and IL-8.92–95 Systemic inflamma-
tion is associated with cellular activation that involves cellular
adhesion molecules, toll-like receptors, matrix metalloprotei-
nase, and nuclear factor-B activation. The resulting interplay
between endothelium, monocytes, and platelets might be
proatherogenic,96–99 contributing indirectly to atherogenesis or
to adverse cardiovascular outcomes related to atheromatous
plaque rupture in subjects with periodontitis.96,97,100 There are
also data to suggest that the inflamed periodontium produces
CRP locally, but to what extent locally produced CRP accounts
for higher circulatory CRP levels in periodontitis has not been
determined.101,102
Indirect Mechanisms: Mimicry
Molecular mimicry has been raised as a possible mechanism
linking periodontal infection with atherosclerosis. Molecular
mimicry is thought to occur when sequence similarities between
foreign and self-peptides produce cross-activation of auto-
reactive T or B cells that can lead to tissue pathology or
autoimmunity.103 Cross-reactive autoantibodies to periodontal
bacterial lipopolysaccharides and heat shock proteins have been
identified96–99 and invoked as a potential explanation for the
putative relationship between PD and ASVD.104 Expression of
host protective heat shock proteins (HSPs) such as HSP60 on
endothelial cells may be induced by a variety of factors,
including cytokines and shear stress, and antibodies to HSP60
have been associated with higher morbidity and mortality from
atherosclerotic ASVD.105 Proponents of molecular mimicry as a
link between PD and ASVD suggest that endothelial damage
may be aggravated by an immune response to bacterial HSP,
such as the molecular chaperone GroEL, present in P gingivalis
and other periodontopathic bacteria.104 Host antibodies directed
against P gingivalis GroEL have cross-reactivity with HSP60 on
human endothelial cells.106 Moreover, cross-reactive T cells
have been found in diseased periodontal tissue, peripheral blood,
and atherosclerotic lesions.107 Studies in experimental animals
lend further support to the hypothesis that cross-reactivity of the
immune response to bacterial HSP has a role in accelerating
atherosclerosis. In murine models, atherosclerosis is augmented
by immunization with recombinant HSP.108 Apolipoprotein
E–deficient mice infected with P gingivalis have accelerated
development and progression of atherosclerosis compared with
control mice.109–111
Direct Mechanisms: Bacteremia and Vascular
Infection by Periodontal Pathogens
Adults harbor more than a billion bacteria in their mouths.
Although the flora varies in different oral regions, the area of
greatest potential relevance to atherosclerosis is the periodon-
tal pocket. The total surface area of the pockets in patients
with periodontitis is estimated to be between 8 and 20 cm2,
and regions of ulceration in the pocket place the bacterial
biofilm in close proximity to the circulation.112
Bacteremia that originates from the mouth is a common event
that can occur during chewing and tooth brushing. It potentially
occurs multiple times per day in individuals with some degree of
gingivitis and periodontitis.113 A comprehensive search of the
literature provides a list of275 bacterial species that have been
identified in blood cultures after routine daily events or dental
procedures.114,115 The nature of the bacterial species that enter
the circulation reflects the resident flora at that location, from
those that colonize the supragingival region down to the deep
subgingival sulcus. Viridans group streptococci represent a
significant proportion of the flora around teeth, particularly in
dental biofilm that grows above the gingival crest (gum line). In
contrast, deeper periodontal pockets harbor other microbes, such
as anaerobic microorganisms and gram-negative species. A
strong association between the incidence of bacteremia after
tooth brushing and 3 indices of oral hygiene and gingival disease
(plaque, calculus, and gingival bleeding) has been demonstrated;
moreover, these associations strengthen as the indices increase in
severity.113 These data strongly suggest that the gingival sulcus
is the main source and portal to the bloodstream for oral bacterial
species detected in the blood.114–118
From there, periodontal organisms circulate in the blood-
stream either within phagocytic cells or extracellularly and
subsequently are deposited in an atheromatous plaque. Common
PD pathogens including P gingivalis adhere to and invade
various human vascular cells in culture.119–121 Infection of aortic
endothelial cells by P gingivalis induces a procoagulant response
that might contribute to a vasculopathic role.121
Periodontal bacterial components have been demonstrated in
human atheromatous plaques at various sites (Table 3). For
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example, in a single-center study of 35 patients undergoing valve
replacement for regurgitant lesions and 27 patients undergoing
thoracoabdominal aortic aneurysm repair, cariogenic Strepto-
coccus mutans was detected in 69% of heart valves and 74% of
atheromatous plaque specimens.108 The frequency of detection
of other bacteria was much lower. Fiehn et al159 failed to isolate
viable oral bacteria from atheromas of 79 surgical specimens of
carotid or femoral arteries but did detect DNA of periodontal
pathogens. Similarly, Haraszthy et al140 found that 80% of 50
carotid endarterectomy specimens were positive in 1 or more of
the polymerase chain reaction assays for A actinomycetemcomi-
tans, T forsythia, P gingivalis, and P intermedia. In 33 patients
with advanced chronic periodontitis scheduled for carotid end-
arterectomy, bacterial DNA was extracted from subgingival
plaque samples and carotid atheromas.160 Bacterial DNA was
detected in 31 of 33 endarterectomy specimens; however, none
of the samples tested positive for DNA of periodontal pathogens
when species-specific primers for detection of periodontal
pathogens were used.160 Similarly, Cairo et al161 could not
demonstrate periodontal bacteria in carotid plaque in a case-
control study involving 52 subjects (26 dentate patients in the
case group; the control group included 26 edentulous patients)
Table 3. Microbiology of the Atherosclerotic Plaque
Evidence Microorganisms References
1. Seroepidemiological data Chlamydophila pneumoniae 122–126
Mycoplasma pneumoniae 127
CMV 122, 128–130
HSV 131
Hepatitis B virus carriers 132
Hepatitis C virus 133
2. Immunocytochemistry in tissue Chlamydophila pneumoniae 122, 134–136
CMV, HSV type 1 135, 136
Porphyromonas gingivalis, Streptococcus sanguis 136
3. Electron microscopy in tissue Herpes virus 137
Mycoplasma pneumoniae 138
Chlamydophila pneumoniae 122
4. Microbial nucleic acid in tissues by
means of PCR amplification
Multiple bacterial species (5–22 species/specimen) that
included staphylococci, streptococci, Proteus vulgaris,
Klebsiella pneumoniae
139
Periodontal pathogens (Porphyromonas gingivalis, Tannerella
forsythia, Aggregatibacter actinomycetemcomitans,
Prevotella intermedia)
140
Chlamydophila pneumoniae 122, 134, 139, 141, 142
Helicobacter pylori 142
HSV 143
CMV 144–146
Fungi 147
5. In situ hybridization in atheroma Mycoplasma pneumoniae 138
Chlamydophila pneumoniae 122
Herpes simplex virus 143, 148
6. Experimental animal models CMV 149, 150
HSV 151
Chlamydophila pneumoniae 152, 153
Influenza A virus 154
Porphyromonas gingivalis 155
Mycoplasma pneumoniae 153
7. Cell cultures that implicate a
variety of microorganisms in the
induction of atherosclerosis
119, 156, 157
8. Recovery of viable microorganisms
in cultures of human atheroma
Chlamydophila pneumoniae 122, 158
The microorganisms that have been implicated in the pathogenesis of atherosclerosis include bacteria (eg, dental plaque
microorganisms such as Porphyromonas gingivalis; Chlamydophila formerly Chlamydia pneumoniae; and Helicobacter pylori),
viruses (eg, herpes simplex virus-1; cytomegalovirus; hepatitis B and C viruses; and influenza A virus), and fungi. The evidence for
specific microorganisms is derived from the studies cited above.
CMV indicates cytomegalovirus; HSV, herpes simplex virus; and PCR, polymerase chain reaction.
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scheduled for carotid endarterectomy. A small study of 22
patients with periodontitis undergoing coronary artery bypass
graft surgery found that periodontal samples from the group with
severe periodontitis had a higher prevalence and biomass of
bacterial species than did the moderate periodontitis group;
however, in combined vessel samples, this prevalence was
statistically significant for only 8 of 20 bacterial species. Inter-
estingly, healthy internal mammary artery and saphenous vein
specimens had a higher prevalence of periodontal bacteria than
did atheromatous plaque specimens in patients with severe
periodontitis, which argues against a causal role of direct
periodontal pathogen invasion.162
Beyond the current interest in PD, the role of infection in the
evolution of ASVD has been the subject of extensive investiga-
tion (Table 3). Several infective agents have been proposed,
including cytomegalovirus, Helicobacter pylori, and particularly
Chlamydophila pneumonia, which has been the most heavily
studied. These studies have included in vitro and animal infec-
tion models, human seroepidemiological investigations, and
clinical trials of antichlamydial antibiotics to prevent ACS.163,164
C pneumoniae or its DNA have been demonstrated in human
atheromatous plaques, prompting the hypothesis that this agent
might initiate or promote the development of these vascular
lesions.165
Recovery of viable microorganisms in cultures of human
atheroma has been difficult,122,158 and results of seroepidemio-
logical, polymerase chain reaction, immunohistochemical, and
in situ hybridization investigations have been criticized for
methodological problems.122 It has been hypothesized that iden-
tified pathogens may be innocent bystanders or that total
pathogen burden may be a more relevant marker of risk than
evidence of individual microbial infections alone.166
Numerous studies have examined the effect of antichla-
mydial antibiotic therapy on outcomes in patients with
coronary artery disease. Of note, systemic antibiotics alone
would not be expected to lead to a long-term resolution of
chronic periodontitis, in which bacteria reside in a biofilm. In
patients with hemodynamically significant coronary artery
disease, the AZACS (AZithromycin in Acute Coronary Syn-
drome), WIZARD (Weekly Intervention with Zithromax for
Atherosclerosis and its Related Disorders), and ACADEMIC
(Azithromycin in Coronary Artery Disease: Elimination of
Myocardial Infarction with Chlamydia) studies did not dem-
onstrate cardiovascular benefit at 6, 14, and 24 months’
follow-up, respectively, after treatment with azithromycin.167–169
Several other antibiotic studies also did not demonstrate a
significant reduction in primary cardiovascular or mortality end
points, including patients with recent ACS.163,164,170,171 One
study found that antibiotic use was associated with reduced
cardiovascular events but did not improve mortality.172 A re-
cently published systematic review and meta-analysis focused
on clinical trials that were prospective, randomized, and placebo
controlled.173 Eleven trials that involved 19 000 patients were
included in the meta-analysis. Antibiotic regimens were highly
variable and included short, intermittent, and prolonged periods
of administration that included macrolides, azalides, and a
fluoroquinolone. For the defined end points of all-cause mortal-
ity, MI, and combined MI and unstable angina, there was no
demonstrable benefit of antibiotic therapy.173 A systematic
review by Voils et al174 did not find sufficient evidence for a role
for antibiotics in secondary prevention of adverse cardiovascular
events or death in symptomatic coronary heart disease (CHD).
Several randomized, placebo-controlled trials to date have
examined the impact of anti-Chlamydophila antibiotic ther-
apy in patients with peripheral artery disease.175–178 Four
studies enrolled 1300 patients; 3 of the 4 studies demon-
strated no benefit in peripheral artery disease–related out-
comes among antibiotic recipients. In the absence of evidence
supporting improved outcomes, there has been no recommen-
dation from professional societies for antibiotic therapy in the
absence of sepsis for patients with MI, unstable angina, periph-
eral artery disease, or asymptomatic coronary artery disease.
Evidence for an Association Between PD
and Cardiovascular Disease
Observational Studies With Clinical Outcomes
Tables 4 through 6 summarize data from epidemiological studies
that report odds ratios, hazard ratios, or relative risk estimates
and use PD as an exposure for ASVD-related outcomes. Spe-
cifically, Table 4 summarizes studies that focused on ASVD.
Table 5 includes studies that evaluated evidence related to acute
MI or ACS, and Table 6 lists studies related to stroke or cerebral
vascular accident. In these studies, PDs as exposure variables
have been broadly defined by a variety of measures that include
self-reported assessments of tooth loss or periodontal status;
clinically or radiographically assessed gingival inflammation
and extent and severity of pathological periodontal pockets or
clinical attachment loss; bacterial colonization by specific peri-
odontal species; and serum IgG and IgA antibody titers to
periodontal pathogens or specific bacterial antigens.
Table 4 includes data from a total of 42 studies. Of these, 26
used clinical or radiographic assessments, and 8 self-reported
data on dental or periodontal status; 5 studies analyzed exclu-
sively data on tooth loss and 7 self-reported data on tooth loss;
5 used serological assessments of antibody titers to periodontal
microbiota, and 1 study described bacterial colonization patterns.
Among the 26 studies that used clinical or radiographic mea-
sures of PD, 18 reported a positive association between poor
periodontal status and increased odds ratio, hazard ratio, or
relative risk for ASVD-related outcomes in adjusted analyses,
and another 2 studies reported positive associations in unad-
justed analyses. Six studies reported no associations between PD
and ASVD-related outcomes after use of multivariate models.
Among the studies that analyzed tooth loss data, 10 reported a
positive, statistically significant association between advanced
tooth loss or edentulism and poor ASVD-related outcomes; 1
study reported a similar association in women only, whereas
another found an association for ASVD only and not for CHD;
and 2 studies reported no association. Among the studies that
used serological assessments, 3 reported positive associations
between specific elevated titers and ASVD events, whereas 2
reported no associations. Finally, the single study that used bacterial
colonization patterns as a measure of exposure reported a positive
association between pathogen burden and ASVD outcomes.
A total of 15 studies that examined the association between
PD and MI, ACS, or obstructive disease in ACS patients are
summarized in Table 5. The exposure variable was clinical or
radiographic assessments of periodontal status in 8 studies,
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Table 4. Summary of Epidemiologic Observational Studies on the Association Between Periodontal Diseases and CHD/CAD/ASVD
That Reported Estimates for Odds Ratios, Hazard Ratios, or Relative Risk
Study N Country
Age
Range, y* Design Exposure† Outcome Adjustments‡ Measure of Association
Senba et al,
2008179
29 909 Japan 66 Cross-sectional Self-reported
periodontitis or tooth
loss
CHD 1–3, 5, 6, 8, 9 OR in males for periodontitis: 1.51
(0.90–2.52); for tooth loss of 5
teeth: 1.54 (0.90–2.62); OR in
females for periodontitis: 1.48
(0.95–2.32); for tooth loss of 5
teeth: 1.68 (1.08–2.61)
Ylostalo et al,
2006180
8690 Finland NR Cross-sectional Self-reported
gingivitis and tooth
loss
Angina pectoris 3, 4 OR for gingivitis: 1.52 (1.04–2.22);
OR for tooth loss: 1.53 (0.69–3.42)
Beck et al,
200522
5002 United States (subset
of the ARIC study)
45–64 Cross-sectional Periodontitis
(clinical); serum IgG
to 17 species
CHD 1–9 OR for high vs low IgG in
ever-smokers:
Td 1.7 (1.2–2.3)
Pi 1.5 (1.1–2.0)
Co 1.5 (1.1–2.1)
Vp 1.7 (1.2–2.3);
OR for high vs low IgG in
never-smokers:
Pn 1.7 (1.1.–2.6)
Aa 1.7 (1.2–2.7)
Co 2.0 (1.3–3.0)
No association with clinical
periodontal status
Elter et al,
2004181
8363 United States
(ARIC)
52–75 Cross-sectional Periodontitis
(clinical); Tooth loss
CHD 5–9, 21 OR for combined high attachment
loss and tooth loss:1.5 (1.1–2.0);
OR for edentulism: 1.8 (1.4–2.4)
Pussinen et
al, 200319
1163 Men Finland 45–74 Cross-sectional Serum IgG to Aa and
Pg
CHD 1, 3–5, 7–9 OR for high combined titer: 1.5
(0.95–2.5)
Lowe et al,
2003182
1958 Scotland 25–74 Cross-sectional Self-reported
edentulism
ASVD 1, 3–5 OR 1.55 (1.13–2.13)
Persson et
al, 2002183
1084 United States 60–75 Cross-sectional Periodontitis
(radiographic)
Carotid calcification Unadjusted OR for bone loss: 2.1 (1.3–3.2)
Buhlin et al,
2002184
1577 Sweden 41–84 Cross-sectional Self-reported oral
status
ASVD Unadjusted OR for bleeding gums: 1.60
(1.19–2.15);
OR for loose teeth: 0.96
(0.62–1.48);
OR for deep pockets: 1.08
(0.78–1.51);
OR for dentures:
1.57 (1.13–2.20)
Starkhammar
Johansson et
al, 2008185
323 Sweden 40–75 Case-control Periodontitis
(clinical/radiographic)
CHD 1, 5 OR 5.74 (2.07–15.90)
Amabile et
al, 2008186
131 France NR Case-control Periodontitis (clinical) CAD 1, 3–9 OR 2.38 (1.43–3.98)
Colhoun et
al, 200876
400 England 30–55 Case-control
(type 1
diabetes
mellitus)
Serum IgG (Pg, Aa) CA calcification 1–9 OR for those having both titers
above the median: 1.4 (0.8–2.6)
Nonnenmacher
et al, 200718
90 Germany 40–80 Case-control Periodontitis (clinical) CHD 1–3, 5, 9 OR 3.2 (1.2–9.0)
Briggs et al,
2006187
171 Ireland 40 Case-control Periodontitis (clinical) CHD 1–6, 10 OR 3.06 (1.02–9.17)
Spahr et al,
200616
789 Germany 43–73 Case-control Periodontitis
(clinical); colonization
by five species (Aa,
Pg, Tf, Pi, Td)
CHD 1, 3–6, 9, 10 OR for incremental increase in
clinical periodontal score by 1
unit: 1.67 (1.08–2.58)
OR for incremental increase in
“total pathogen burden” by 1 log
unit: 1.83 (1.23–2.71)
Geismar et
al, 2006188
250 Denmark NR Case-control Periodontitis
(clinical/radiographic)
CHD 1, 3, 5, 7, 9–11 OR for severe bone loss: 6.6
(1.69–25.6) in ages 60 y
Buhlin et al,
2005189
193 Women Sweden 43–79 Case-control Periodontitis
(clinical/radiographic)
CHD 1, 4–6, 9 OR for high No. of deep pockets:
3.68 (1.68–8.74)
Janket et al,
2004190
506 Finland NR Case-control Periodontitis (clinical;
asymptotic dental
score, ADS)
CHD 7, 14, 15 OR 1.71 (1.36–2.14)
Geerts et al,
2004191
170 Belgium NR Case-control Periodontitis (clinical) CAD 1, 3, 5–8, 10, 11,
16
OR 6.5 (1.8–23)
(Continued)
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Table 4. Continued
Study N Country
Age
Range, y* Design Exposure† Outcome Adjustments‡ Measure of Association
Dorn et al,
201081
884 United States 35–69 Cohort Periodontitis (clinical) Overall ASVD events
(fatal, nonfatal,
revascularization)
1, 3–5, 7, 9, 11, 16,
18, 25
HR for mean attachment level in
never-smokers: 1.43 (1.06–1.91);
in ever-smokers: 0.99 (0.86–1.15)
de Oliveira et
al, 2010192
11 869 Scotland 35 Cohort Self-reported oral
hygiene
ASVD 1, 3–6, 8, 9, 11, 20,
26
HR for tooth brushing less than
once vs at least twice daily: 1.7
(1.3–2.3)
Holmlund et
al, 2010193
7674 Sweden 20–89 Cohort Tooth loss;
periodontitis (clinical)
CHD and ASVD
mortality
1, 3, 5 ASVD mortality: HR for 10 teeth
vs 25 teeth: 4.41 (2.47–7.85);
HR for severe periodontal disease
vs no disease: 1.62 (0.59–4.46).
CHD mortality: HR for 10 teeth
vs 25 teeth: 7.33 (4.11–13.07);
HR for severe periodontal disease
vs no disease: 0.78 (0.27–2.21)
Meurman et
al, 2003194
506 Finland NR Case-control Periodontitis
(clinical/radiographic;
modified dental
index)
CHD 1, 3, 4 OR 1.31 (1.16–1.48)
Dietrich et al,
2008195
1203 United States
(Normative Aging
Study)
21–84 Cohort Periodontitis
(clinical/radiographic)
CHD 1–10 HR for ages 60 y: Clinical, 1.94
(1.23–3.05); radiographic, 2.12
(1.26–3.60). HR for ages 60 y:
Clinical, 0.73 (0.45–1.19);
radiographic: 1.81 (NR)
Heitmann
and
Gamborg,
2008196
2932 Denmark (MONICA) 30–60 Cohort Tooth loss Fatal/nonfatal ASVD,
CHD
1, 2, 4–6, 8–10 HR (5th vs 1st quintile) for ASVD:
1.50 (1.02–2.19); HR for CHD:
1.31 (0.74–2.31)
Pussinen et
al, 2007197
505 Finland (FINRISK
subset)
25–64 Prospective
case-cohort
Serum IgG and IgA
to Aa and Pg
ASVD 1, 3–9 HR for combined high titers: 1.87
(1.13–3.08)
Tu et al,
2007198
12 223 Scotland 39 Cohort Tooth loss ASVD mortality 1, 3–5, 8, 9 HR for those having 9 missing
teeth: 1.35 (1.03–1.77)
Pussinen et
al, 200524
1023 Men Finland (Kuopio
Ischemic Heart
Disease study)
46–64 Cohort Serum IgA and IgG
to Aa, Pg
CHD 1, 4–8, 15 RR for high Aa IgA: 2.0 (1.2–3.3);
RR for high Pg IgA: 2.1 (1.3–3.4)
Saremi et al,
2005199
628 With type
2 diabetes
mellitus
United States (Pima
Indians)
35 Prospective
cohort
Periodontitis
(clinical/radiographic)
ASVD mortality 1, 3, 5–7, 9, 13 HR for severe periodontitis: 3.2
(1.1–9.3)
Holm-
Pedersen et
al, 2005200
125 Sweden 80 Cohort Periodontitis (clinical) Arrhythmia Unadjusted OR 1.3 (0.5–3.5)
Hung et al,
2004201
100 381 United States HPFS
and NHS
40–75 Cohort Self-reported tooth
loss
CHD 1, 5–11, 16 RR for severe tooth loss in men:
1.36 (1.11–1.67); in women: 1.64
(1.31–2.05)
Ajwani et al,
2003202
364 Finland 75–85 Cohort Periodontitis (clinical) ASVD mortality 1, 3–5, 7–9 RR 1.97 (1.01–3.85)
Tuominen et
al, 200374
6527 Finland 30–69 Cohort Periodontitis
(clinical); tooth loss
ASVD mortality 1, 4–8 RR for tooth loss in men: 0.9
(0.5–1.6) in women: 0.3 (0.1–1.0)
RR for periodontitis in men: 1.0
(0.6–1.6) in women: 1.5 (0.6–3.8)
Ajwani et al,
2003203
364 Finland 76–86 Cohort Periodontitis (clinical) CHD mortality 1, 3, 4, 7–9, 19 OR for periodontitis: 1.86
(0.96–3.58); OR for edentulism:
1.90 (1.06–3.39)
Hujoel et al,
2002204
371 United States (subset
of NHANES I with
history of ASVD and
who were dentate)
NR Cohort Periodontitis (clinical) Incident CHD; fatal
CHD
1–12 HR for ASVD and periodontitis: 0.79
(0.54–1.14); HR for ASVD and
gingivitis: 0.76 (0.50–1.15); HR for
fatal ASVD and periodontitis: 0.75
(0.34–1.66); OR for fatal ASVD and
gingivitis: 1.22 (0.57–2.62)
Abnet et al,
2001205
29 584 China 40–69 Cohort Tooth loss ASVD mortality 1, 3, 5 RR 1.28 (1.17–1.40)
Jansson et
al, 2001206
1393 Sweden 18–66 Cohort Periodontitis
(clinical/radiographic)
ASVD mortality 1, 3, 5, 19 Incidence OR for periodontitis in
ages 45 y: 2.7 (P0.04)
Howell et al,
2001207
22 071 United States
(Physicians Health
Study)
40–84 Cohort Self-reported
periodontitis
ASVD mortality 1, 5, 6, 8–11, 19 RR 1.00 (0.79–1.26)
Hujoel et al,
200072
8032 (NHANES
I follow-up
study)
United States 25–74 Cohort Periodontitis (clinical) CHD events
(mortality,
hospitalization,
revascularization
procedure)
1–12 HR for gingivitis: 1.05 (0.88–1.26);
HR for periodontitis: 1.14
(0.96–1.36)
(Continued)
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self-reported periodontitis in 2 studies, tooth loss as the sole
exposure in 1 study, levels of systemic antibodies to periodontal
pathogens in 2 studies, colonization levels by 6 periodontal
species in 1 study, and benzoyl-DL-arginine naphthylamide
(BANA), which reflects colonization by 3 gram-negative anaer-
obic bacteria associated with periodontitis (P gingivalis, T
denticola, and T forsythia), in 1 study. Poor periodontal status
was positively associated with higher risk for MI-associated
events in all 8 studies that assessed it by means of a clinical
periodontal examination. In contrast, 2 studies that used self-
reported information on oral status184,207 found no association
between poor periodontal status and MI. Tooth loss was not
associated with MI-related events in any of the 3 studies that
presented such analyses. The study that used periodontal micro-
bial colonization as the exposure marker found a positive
association between high colonization by 2 periodontal patho-
gens and MI. Use of BANA as a surrogate marker for bacterial
colonization in another study suggested a positive association
between BANA values and risk for ACS. Two serological
studies revealed positive associations between high specific
titers and MI-related events, the first for any of the 4 IgG titers
tested,26 whereas the second one20 found a positive association
only for IgA against P gingivalis.
Lastly, Table 6 summarizes findings from 22 studies that
examined stroke as the dependent variable. With respect to
exposure, 5 studies used tooth loss data exclusively, 11
included clinical or radiographic assessments of periodontal
status, 4 used self-reported information on oral/periodontal
health, and 3 examined antibody responses to periodontal
bacteria. Six studies that used tooth loss data reported a
positive association between tooth loss and edentulism and
stroke, but another 6 failed to document a statistically significant
association. In contrast, 11 studies reported positive associations
between poor periodontal status and stroke, whereas only 3
studies did not. Among the serological studies, 1 showed no
association between high titers and stroke,80 1 showed a statis-
tically significant inverse association between high serum anti-
bodies to A actinomycetemcomitans leukotoxin and stroke in
women only,226 and 1 showed a statistically marginal association
between high serum IgA to A actinomycetemcomitans and P
gingivalis that was differentially based on ASVD history.21
Observational Studies Using Noninvasive Imaging
Correlates or Surrogate Markers of ASVD
Many imaging tools and surrogate markers for atherosclerosis
are in clinical and experimental use. Some identify anatomic
changes at subclinical stages, whereas others reflect func-
tional aberrations in the vasculature or end-organ impact. A
systematic review on the use of a broad spectrum of such
methods in subjects with PD included screening computed
tomography of the coronary arteries, ultrasound of the carotid
arteries, magnetic resonance imaging, ankle-brachial index, mi-
croalbuminuria and other biochemical measures of kidney dys-
function, flow-mediated vasodilation (FMD) of the brachial
artery (as a marker of endothelial function), and pulse waveform
analysis. The authors found that these measures are not highly
Table 4. Continued
Study N Country
Age
Range, y* Design Exposure† Outcome Adjustments‡ Measure of Association
Morrison et
al, 1999208
10 368 Canada 35–84 Cohort Periodontitis (clinical) CHD mortality 1, 3, 5–8 RR for severe gingivitis: 2.15
(1.25–3.2); RR for periodontitis:
1.37 (0.80–2.35); RR for
edentulism: 1.90 (1.17–3.10)
Joshipura et
al, 1996209
44 119 men
(Health
Professionals’
Follow-Up
Study)
United States 40–75 Cohort Self-reported oral
health status
Incident CHD 1, 5, 9–11, 20, 21 RR in those with periodontitis:
1.04 (0.86–1.25); RR among those
reporting periodontitis and 10
teeth: 1.67 (1.03–2.71)
Beck et al,
1996210
1147 Men United States 21–80 Cohort Periodontitis
(clinical/radiographic)
Incident CHD 1, 7–9 Incidence OR for those with
“high” bone loss: 1.5 (1.04–2.14);
incidence OR for those with
pockets 3 mm at all their teeth:
3.1 (1.30–7.30)
DeStefano et
al, 199377
9760 (NHANES
I follow-up
study)
United States 25–74 Cohort Periodontitis (clinical) Incident fatal and
nonfatal CHD
1–11 RR for gingivitis: 1.05 (0.88–1.26);
RR for periodontitis: 1.25
(1.06–1.48); RR for edentulism:
1.23 (1.05–1.44)
Studies are grouped according to design (cross-sectional, case-control, or cohort) and sorted by year of publication.
CHD indicates coronary heart disease; CAD, coronary artery disease; ASVD, atherosclerotic vascular disease; OR, odds ratio; NR, not recorded; ARIC, Atherosclerosis
Risk In Communities; Td, Treponema denticola; Pi, Prevotella intermedia; Co, Capnocytophaga ochracea; Vp, Veillonella parvula; Pn, Prevotella nigrescens; Aa,
Aggregatibacter actinomycetemcomitans; Pg, Porphyromonas gingivalis; CA, coronary artery; Tf, Tannerella forsythia; ADS, asymptotic dental score; HR, hazard ratio;
MONICA, Monitoring Trends and Determinants in Cardiovascular Disease; FINRISK, Finland Cardiovascular Risk Study; RR, relative risk; HPFS, Health Professionals
Follow-Up Study; NHS, National Health Service; and NHANES I, National Health and Nutrition Examination Survey I.
*For cohort studies, the reported age range applies to the baseline examination.
†Describes how periodontitis/oral health status was assessed (clinically, radiographically, by self-reported information, by serological assessment of titers to specific
periodontal bacteria, or by assessment of oral microbial colonization).
‡Adjustments: Numbers describe the following variables: (1) Age; (2) race or ethnicity; (3) sex; (4) socioeconomic status (income and/or education); (5) smoking habits; (6)
diabetes (presence or duration/hemoglobin A1c); (7) hyperlipidemia (or low-density lipoprotein cholesterol and/or high-density lipoprotein cholesterol and/or triglycerides); (8)
hypertension (or systolic and/or diastolic blood pressure); (9) body mass index or waist/hip ratio or obesity; (10) alcohol consumption; (11) physical activity; (12) marital status;
(13) microalbuminuria; (14) C-reactive protein; (15) fibrinogen; (16) diet; (17) vitamin E intake; (18) statin intake; (19) history of ASVD; (20) family history of ASVD; (21) current
access to dentist; (22) renal disease; (23) papillary bleeding score; (24) dependent living; (25) hypertension medication; (26) frequency of dental visits; (27) oral hygiene; (28)
missing teeth; (29) DMFT index (decayed, missing, filled teeth); (30) family history of diabetes; and (31) family history of hypertension.
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correlated with each other and do not fully substitute for studies
of clinical ASVD end points.235 Nevertheless, these methods
have proved useful in clinical investigations of specific ASVD
manifestations in defined patient cohorts and have been applied
to the question of a possible PD/ASVD link.
Association of Periodontitis With Subclinical Carotid or
Coronary Artery Disease
Detection of ASVD before its clinical presentation is an impor-
tant goal. Direct visualization of the coronary circulation with
computed tomographic methods can reveal calcification of
vessels that identifies the atherosclerotic process and may have
a role in stratifying patient risk. Atherosclerosis in noncoronary
arterial beds such as the carotid arteries or peripheral arteries is
correlated with coronary artery involvement, and ultrasound-
based measurement of carotid intima-media thickness (cIMT) is
considered a surrogate marker of coronary artery disease that has
been validated in large population studies such as the Multi-
Ethnic Study of Atherosclerosis (MESA).236
Table 5. Summary of Epidemiological Observational Studies on the Association Between Periodontal Diseases and Myocardial
Infarction or Acute Coronary Syndrome That Reported Odds Ratios, Hazard Ratios, or Relative Risk
Study N Country
Age
Range, y* Design Exposure† Outcome Adjustments‡ Measure of Association
Gotsman et al,
2007211
201 Israel NR Cross-sectional Periodontitis (clinical) ACS 1, 5, 7, 8 OR for % of teeth with CAL 5 mm:
1.03 (1.01–1.04)
Accarini and de
Godoy, 2006212
361 Brazil 27–89 Cross-sectional Periodontitis (clinical) Obstructive disease
in ACS patients
Unadjusted OR 2.57 (1.19–5.54)
Holmlund et al,
2006213
4254 Sweden 20–70 Cross-sectional Periodontitis
(clinical/radiographic)
Self-reported,
hospital-treated MI
1, 3, 5 OR for bone loss in ages 40–60 only:
2.69 (1.12–6.46)
Buhlin et al,
2002184
1577 Sweden 41–84 Cross-sectional Self-reported oral
status
Self-reported MI Unadjusted OR for bleeding gums: 0.55 (0.22–1.36);
OR for loose teeth: 0.98 (0.32–3.04);
OR for deep pockets: 1.32 (0.51–3.38);
OR for dentures: 1.04 (0.47–2.30)
Arbes et al,
1999214
5564 (NHANES III) United States 40–90 Cross-sectional Periodontitis (clinical) Self-reported heart
attack
1–9 OR for highest vs lowest extent of
attachment loss: 3.77 (1.46–9.74)
Adriankaja et
al, 2011215
1060 United States 35–69 Case-control Presence of 6
periodontal
pathogens (Pg, Tf,
Pi, Cr, Fn, Es)
MI 1, 3–8 OR for Tf: 1.62 (1.18–1.22); Pi: 1.4
(1.02–1.92)
Lund Håheim
et al, 200826
1173 men Norway 48–77 Case-control Serum IgG to Pg, Aa,
Td, and Tf
Self-reported MI 5–9, 14 OR for seropositivity for any of the 4
titers: 1.30 (1.01–1.68)
Rech et al,
2007216
114 Brazil NR Case-control Periodontitis (clinical) ACS 1, 3, 5, 6 OR 4.5 (1.3–15.6)
Rubenfire et al,
2007217
440 United States NR Case-control Positive BANA test ACS 1, 3, 5, 22,
23
OR in BANA-positive participants: 3.95
(1.61–9.71)
Andriankaja et
al, 2007218
1461 United States 35–69 Case-control Periodontitis (clinical) Nonfatal MI 1, 3, 5–8 OR for mean attachment loss: 1.46
(1.26–1.69)
Cueto et al,
2005219
149 Spain 40–75 Case-control Periodontitis (clinical;
partial recording)
MI 1, 3, 5–7, 11 OR for extensive periodontitis: 3.31
(1.42–7.71)
Pussinen et al,
200420
126 Finland 30–59 Case-control Serum IgA and IgG
to Pg and Aa
Nonfatal and fatal
MI
5–9 OR for 4th vs 1st quartile of titer level;
OR for Aa IgA: 0.60 (0.20–1.83); OR for
Aa IgG: 0.42 (0.14–1.31); OR for Pg IgA:
3.99 (1.22–13.10); OR for Pg IgG: 0.54
(0.18–1.60)
Lopez et al,
2002220
61 Chile 30–50 Case-control Periodontitis (clinical) Hospitalization
because of MI,
unstable angina, or
angina pectoris
5, 6, 8 OR for mean attachment level: 3.17
(1.31–7.65); OR for mean probing
depth: 8.64 (1.22–61.20); OR for mean
No. of teeth: 0.93 (0.83–1.04)
Syrjala et al,
2009221
392 Never-smokers Finland 75 Cohort Tooth loss MI 1, 3, 4, 6–11 Prevalence proportion ratio for No. of
teeth (continuous): 1.01 (0.97–1.05);
Prevalence proportion ratio for dentate
vs edentulous: 0.9 (0.5–1.8)
Howell et al,
2001207
22 071 United States
(Physicians Health
Study)
40–84 Cohort Self-reported
periodontitis
Nonfatal MI 1, 5, 6,
8–11, 19
RR 1.01 (0.82–1.24)
Studies are grouped according to design (cross-sectional, case-control, or cohort) and sorted by year of publication.
NR indicates not recorded; ACS, acute coronary syndrome; OR, odds ratio; CAL, clinical attachment level; MI, myocardial infarction; NHANES III, National Health and Nutrition
Examination Survey III; Pg, Porphyromonas gingivalis; Tf, Tannerella forsythia; Pi, Prevotella intermedia; Cr, Campylobacter rectus; Fn, Fusobacterium nucleatum; Es,
Eubacterium saburreum; Aa, Aggregatibacter actinomycetemcomitans; Td, Treponema denticola; BANA, benzoyl-DL-arginine naphthylamide; and RR, relative risk.
*For cohort studies, the reported age range applies to the baseline examination.
†Describes how periodontitis/oral health status was assessed (clinically, radiographically, by self-reported information, by serological assessment of titers to specific
periodontal bacteria, or by assessment of oral microbial colonization).
‡Adjustments: Numbers describe the following variables: (1) Age; (2) race or ethnicity; (3) sex; (4) socioeconomic status (income and/or education); (5) smoking
habits; (6) diabetes (presence or duration/hemoglobin A1c); (7) hyperlipidemia (or low-density lipoprotein cholesterol and/or high-density lipoprotein cholesterol and/or
triglycerides); (8) hypertension (or systolic and/or diastolic blood pressure); (9) body mass index or waist/hip ratio or obesity; (10) alcohol consumption; (11) physical activity;
(12) marital status; (13) microalbuminuria; (14) C-reactive protein; (15) fibrinogen; (16) diet; (17) vitamin E intake; (18) statin intake; (19) history of ASVD; (20) family history
of ASVD; (21) current access to dentist; (22) renal disease; (23) papillary bleeding score; (24) dependent living; (25) hypertension medication; (26) frequency of dental visits;
(27) oral hygiene; (28) missing teeth; (29) DMFT index (decayed, missing, filled teeth); (30) family history of diabetes; and (31) family history of hypertension.
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Table 6. Summary of Epidemiologic Observational Studies on the Association Between Periodontal Diseases and Stroke That
Reported Odds Ratios, Hazard Ratios, or Relative Risk
Study N Country
Age
Range, y* Design Exposure† Outcome Adjustments‡ Measure of Association
Lee et al,
2006222
5123 United States 60 to 76 Cross-sectional PHS (a composite index of
periodontitis and tooth
loss)
Self-reported
history of stroke
1, 5, 6, 8, 10, 14 OR for PHS class 5 vs class 1: 1.56
(0.95–2.57)
Elter et al,
2003223
10 906 United States NR Cross-sectional Periodontitis (clinical);
edentulism
Ischemic stroke or
TIA
1–9, 21 OR for highest quartile of AL: 1.3
(1.02–1.7); OR for edentulism: 1.4
(1.5–2.0)
Buhlin et
al, 2002184
1577 Sweden 41–84 Cross-sectional Self-reported oral status Stroke§ Unadjusted OR for bleeding gums: 1.83 (0.78–4.31);
OR for loose teeth: 1.83 (0.66–5.12); OR
for deep pockets: 0.68 (0.22–2.05); OR
for dentures: 1.81 (0.74–4.42)
Kim et al,
2010224
379 Korea 40–79 Case-control Periodontitis (clinical) Hemorrhagic
stroke
1, 3–6, 8–10, 19,
26–31
OR for presence of attachment level
6 mm: 2.53 (1.14–5.61)
Pradeep et
al, 2010225
200 India 33–68 Case-control Periodontitis (clinical) Acute cerebral
ischemia
1, 3–6, 8, 10, 27 OR for mean pocket depth 4.5 mm:
8.5 (1.1–68.2)
Sim et al,
200879
479 Korea 40–79 Case-control Periodontitis (clinical) Stroke§ 4–6, 8–10,
19–21
OR for severe periodontitis: 4.30
(2.27–8.16)
Pussinen
et al,
200780
893 Finland 45–74 Case-control Serum IgG and IgA to Aa
and Pg
Stroke§ 1, 4, 5, 7–10 OR for seropositivity for Aa IgA: 0.83
(0.62–1.1); OR for Aa IgG: 0.93
(0.66–1.32); OR for Pg IgA: 1.22
(0.91–1.65); OR for Pg IgG: 1.31
(0.97–1.76)
Johansson
et al,
2005226
819 Sweden 25–74 Case-control Serum antibodies to Aa
leukotoxin
Stroke§ 4–9 OR for seropositivity in men: 0.88
(0.52–1.51); OR for seropositivity in
women: 0.28 (0.13–0.59)
Dorfer et
al, 2004227
603 Germany 18–25 Case-control Periodontitis, gingivitis
(clinical/radiographic)
Ischemic stroke 1, 3–6, 8, 19 OR for severe gingivitis: 18.29
(5.84–57.26); OR for CAL 6 mm: 7.38
(1.55–15.03); OR for severe bone loss:
3.62 (1.58–8.28)
Pussinen
et al,
200421
500 Finland 45–64 Case-control Serum IgG and IgA to Pg
and Aa
Stroke 1, 3, 5–10 OR for IgA seropositivity to Aa in
participants free of ASVD at baseline: 1.6
(1.0–2.6); OR for IgA seropositivity to Pg
in participants with ASVD at baseline: 2.6
(1.0–7.0)
Grau et al,
2004228
771 Germany 18–75 Case-control Periodontitis (clinical) Ischemic stroke or
TIA
1, 3–6, 8, 10, 19 OR for clinical attachment loss 6 mm:
4.34 (1.85–10.2)
Loesche et
al, 1998229
401 United States 60 Case-control Periodontitis (clinical) CVA 1–3, 5–7, 9, 24 OR for % teeth with AL6 mm: 1.04
(1.01–1.07); OR for % of teeth with PD
6 mm: 0.96 (0.92–1.01); OR for 15–28
teeth present vs 1–14 teeth present:
3.29 (1.33–8.16)
Holmlund
et al,
2010193
7674 Sweden 20–89 Cohort Tooth loss; periodontitis
(clinical)
Stroke mortality 1, 3, 5 HR for 10 teeth vs 25 teeth: 0.91
(0.24–3.49); HR for severe periodontal
disease vs no disease: 1.39 (0.18–10.45)
Choe et
al, 2009230
867 256 Korea 30–95 Cohort Tooth loss Stroke§ 1, 5–11 HR for men having 7 missing teeth:
1.3 (1.2, 1.4); HR for women having 7
missing teeth: 1.2 (1.0, 1.3)
You et al,
2009231
2862 United States 45 to 85 Cohort Self-reported tooth loss Self-reported
stroke
1–8, 14, 19 OR for participants having 17 missing
teeth: 1.27 (1.09, 1.49)
Syrjala et
al, 2009221
392 Never-smokers Finland 75 Cohort Tooth loss Stroke§ 1, 3, 4, 6–11 Prevalence proportion ratio for No. of
teeth (continuous): 1.02 (0.94–1.08);
Prevalence proportion ratio for dentate vs
edentulous: 0.9 (0.2–2.8)
Tu et al,
2007198
12 223 Scotland 39 Cohort Tooth loss Stroke§ 1, 3–5, 8, 9 HR for those having 9 missing teeth:
1.64 (0.96–2.80)
Abnet et
al, 2005232
29 584 China 40–69 Cohort Tooth loss Fatal stroke 1, 3, 5, 8, 9 RR for those with less than the median
age-specific No. of teeth: 1.11
(1.01–1.23)
Joshipura
et al,
2003233
41 380 Men United States 40–75 Cohort Self-reported
periodontitis/tooth loss
Ischemic stroke 1, 4–11, 17 HR for those with 24 teeth: 1.57
(1.24–1.98); HR for those with
periodontitis: 1.33 (1.03–1.70)
Wu et al,
2000234
9962 United States 25–74 Cohort Gingivitis, periodontitis
(clinical); edentulism
Ischemic stroke 1–10 RR for gingivitis: 1.24 (0.74–2.08); RR
for periodontitis: 2.11 (1.30–3.42); RR for
edentulism: 1.41 (0.96–2.06)
(Continued)
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Increased cIMT has correlated with PD in several associ-
ation studies, which demonstrated that severe periodontitis,237
high subgingival colonization concentrations by specific peri-
odontal pathogens,15 and high serum IgG titers against individ-
ual periodontal bacteria23 were significantly related to increased
cIMT in adjusted analyses. A retrospective case study by
Beckstrom et al238 found a significant direct correlation between
periodontal bone loss and carotid artery calcifications on pan-
oramic radiographs. So¨der et al239 concluded in a case-control
study that cIMT and intima-media area were significantly higher
in women with PD than in control subjects. An earlier prospec-
tive case-control study by So¨der et al240 also found significantly
higher mean values of cIMT and carotid intima-media area in
patients with PD compared with control subjects. PD was a
principal independent predictor of the common carotid intima-
media area (odds ratio, 5.20; P0.003) and cIMT (odds ratio,
4.64; P0.004) in a multiple logistic regression model.240
In patients with chronic kidney disease, Franek et al241 noted
significantly higher serum CRP concentration (13.211.4
mg/L versus 10.414.4 mg/L; P0.05) and cIMT
(0.7420.028 versus 0.6560.019; P0.05) in patients with
advanced periodontitis than in patients without PD. Genctoy
et al242 noted a significant positive correlation between mean
cIMT and gingival index in 83 renal transplant recipients with
varying degrees of PD even in the absence of systemic inflam-
mation and after adjusting for confounding variables. Des-
varieux et al15 evaluated the relationship between periodontal
microbiology and subclinical atherosclerosis in a dentate subset
of the Oral Infections and Vascular Disease Epidemiology
(INVEST) Study and found that periodontal bacterial burden
was related to cIMT across tertiles of bacterial colonization by a
subset of a priori defined periodontal pathogens (P0.002),
although CRP values were unrelated to periodontal microbial
status (P0.82). In a subset of participants in the Atherosclerosis
Risk in Communities (ARIC) Study who received a complete
periodontal examination, a significant direct relationship be-
tween IgG antibody reactive to oral organisms and subclinical
atherosclerosis by cIMT 1 mm was noted in both ever- and
never-smokers.23
Detection of coronary artery calcium (CAC) by computed
tomography has been promoted as a marker of risk for future
ASVD events. The 2007 ACC/AHA expert consensus statement
on CAC scoring by computed tomography judged that it may be
reasonable to use CAC measurement in asymptomatic patients
with intermediate CHD risk (between 10% and 20% 10-year risk
of estimated coronary events) on the basis of available evidence
that demonstrates incremental risk prediction information in this
selected patient group.243,244 Use of CAC measurements was not
recommended for those in other risk categories or with CHD risk
equivalents. PD was not considered as a clinical factor in the use
of CAC scoring, and no data are available regarding its role in
defining ASVD risk in that patient population.
Association of Periodontitis With Endothelial Dysfunction
Vascular endothelium serves a number of vital cardiovascular
functions, including regulation of vasomotor tone via nitric
oxide and other mediators, prevention of thrombosis, and regu-
lation of interaction between the blood vessel wall and platelets,
leukocytes, and monocytes.245 Endothelial dysfunction may be
the earliest vascular manifestation of ASVD and has been
associated with traditional risk factors associated with ASVD.246
It has also been associated with nontraditional risk factors for
ASVD, including systemic inflammation, obesity, and physical
inactivity, among others.246 Endothelial dysfunction has been
demonstrated among subjects with clinically apparent ASVD,
including coronary and peripheral atherosclerosis, preeclampsia,
congestive heart failure, pulmonary hypertension, and septic
shock.246 Even among patients free of clinically apparent ASVD,
endothelial dysfunction has been associated with an increased
risk of incident cardiovascular adverse events during subsequent
follow-up.246–249 Interventions associated with ASVD risk re-
duction, such as smoking cessation, use of statin therapy, and
angiotensin-converting enzyme inhibitors, improve endothelial
function in clinical trials.246 Other interventions that improved
endothelial function in physiological research studies (eg,
Table 6. Continued
Study N Country
Age
Range, y* Design Exposure† Outcome Adjustments‡ Measure of Association
Howell et
al, 2001207
22 071 United States
(Physicians
Health Study)
40–84 Cohort Self-reported periodontitis Nonfatal stroke 1, 5, 6, 8–11, 19 RR 1.10 (0.88–1.37)
Morrison
et al,
1999208
10 368 Canada 35–84 Cohort Gingivitis, periodontitis
(clinical)
Stroke mortality 1, 3, 5–8 RR for severe gingivitis: 1.81 (0.77–4.25)
RR for periodontitis: 1.63 (0.72–3.67) RR
for edentulism: 1.63 (0.77–3.42)
Studies are grouped according to design (cross-sectional, case-control, or cohort) and sorted by year of publication.
PHS, periodontal health status, a composite index of periodontitis and tooth loss; OR, odds ratio; NR, not recorded; TIA, transient ischemic attack; AL, attachment
level3 mm; Aa, Aggregatibacter actinomycetemcomitans; Pg, Porphyromonas gingivalis; CAL, clinical attachment level; ASVD, atherosclerotic vascular disease; CVA,
cerebral vascular accident; PD, pocket depth; HR, hazard ratio; and RR, relative risk.
*For cohort studies, the reported age range applies to the baseline examination.
†Describes how periodontitis/oral health status was assessed (clinically, radiographically, by self-reported information, by serological assessment of titers to specific
periodontal bacteria, or by assessment of oral microbial colonization).
‡Adjustments: Numbers describe the following variables: (1) Age; (2) race or ethnicity; (3) sex; (4) socioeconomic status (income and/or education); (5) smoking
habits; (6) diabetes (presence or duration/hemoglobin A1c); (7) hyperlipidemia (or low-density lipoprotein cholesterol and/or high-density lipoprotein cholesterol and/or
triglycerides); (8) hypertension (or systolic and/or diastolic blood pressure); (9) body mass index or waist/hip ratio or obesity; (10) alcohol consumption; (11) physical activity;
(12) marital status; (13) microalbuminuria; (14) C-reactive protein; (15) fibrinogen; (16) diet; (17) vitamin E intake; (18) statin intake; (19) history of ASVD; (20) family history
of ASVD; (21) current access to dentist; (22) renal disease; (23) papillary bleeding score; (24) dependent living; (25) hypertension medication; (26) frequency of dental visits;
(27) oral hygiene; (28) missing teeth; (29) DMFT index (decayed, missing, filled teeth); (30) family history of diabetes; and (31) family history of hypertension.
§Ischemic and hemorrhagic stroke.
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L-arginine, antioxidant vitamins), however, have shown no benefit
in clinical end points and have even shown the potential for harm
when studied in large-scale, randomized clinical trials.250,251
A number of tools are used to assess endothelial function in
vivo.246,252 Traditional invasive techniques to assess endothe-
lial function required intracoronary or other intra-arterial
injections of vasoactive substances such as acetylcholine.
More recently, noninvasive methods such as high-resolution
ultrasound assessment of the brachial artery after FMD or
nitroglycerin administration and digital pulse amplitude tonom-
etry have been studied across a broad spectrum of patient
populations.253 Important limitations of these methods have been
described, and their reliable use requires careful attention to
calibration, interobserver variability, ambient temperature, and
hormonal effects in premenopausal women. The degree to which
such exacting methodologies have been applied is not well
defined in many studies, and their conclusions must be inter-
preted with acknowledgement of that limitation.
Endothelial function in humans with PD has been studied in
a small number of subjects, with variable control of the impor-
tant patient, operator, and technical limitations described
above.254–256 Amar and colleagues254 compared endothelial
function as assessed by brachial artery FMD among 26 subjects
with severe PD graded by use of standardized diagnostic criteria
versus 29 control subjects with no evidence of PD. None of the
subjects had known ASVD or documented cardiovascular risk
factors. FMD was significantly reduced among subjects with PD
compared with control subjects (7.8% versus 11.7%; P0.005).
There was no significant difference in the endothelium-
independent vasodilatory response to sublingual nitroglycerin
administration in the 2 groups. CRP levels were significantly
higher among subjects with advanced PD than among control
subjects. In a subsequent analysis, no significant difference in
FMD was found between subjects with mild PD and control
subjects, which suggests a dose-response effect to the degree of
PD and the degree of endothelial dysfunction.254 Seinost and
colleagues256 reported similar impairment in brachial artery
FMD among otherwise healthy subjects with advanced PD
(n30) compared with control subjects (n31; 6.1% versus
8.5%, P0.002). Mercanoglu and colleagues257 reported impair-
ment in both brachial artery FMD and endothelium-independent
vasodilatory response to sublingual nitroglycerin in otherwise
healthy subjects with periodontitis compared with healthy control
subjects. Periodontal therapy was associated with significant im-
provement in both FMD and nitroglycerin response in this cohort.
Higashi and colleagues255 used strain-gauge plethysmography
for assessment of forearm blood flow in response to intra-arterial
infusion of acetylcholine to assess endothelial function in
healthy and hypertensive subjects with and without PD. Among
52 male subjects without ASVD or established risk factors, the
presence of self-reported and dentist-confirmed PD was associ-
ated with a blunted forearm blood flow response to acetylcholine
infusion compared with subjects without PD. There was no
difference in the endothelium-independent response to sodium
nitroprusside. Furthermore, among subjects with PD who were
referred to a 24-week treatment program for PD, there was a
statistically significant improvement in forearm blood flow
response to acetylcholine compared with pretreatment values.
Similar experiments were undertaken by these investigators
among 38 male and female subjects with hypertension with and
without PD.255 Hypertensive subjects with PD had impaired
forearm blood flow response to acetylcholine administration
compared with subjects without PD. Among hypertensive pa-
tients with PD who underwent a treatment program, endothelial
function improved significantly, to levels comparable to reported
values for healthy control subjects.
Association of Periodontitis With Systemic Inflammation
Periodontitis is associated with both local and systemic inflam-
mation. Multiple cytokines and inflammatory markers, including
IL-1, IL-6, IL-8, and tumor necrosis factor, are abundantly
produced locally in the gingiva of patients with periodontitis and
can be recovered in gingival crevicular fluid samples obtained
from involved tooth sites.258,259 Although it has been postulated
that these locally produced inflammatory mediators are intro-
duced into the blood stream, periodontitis has not been shown to
induce a sustained elevation of plasma IL-1260 or tumor
necrosis factor-.261 Nevertheless, chronic periodontal infection
contributes to systemic inflammation characterized by elevation
of acute phase proteins, including inflammatory cytokines such
as IL-6,92 coagulation factors such as fibrinogen,95 and CRP.92–95
CRP has been linked to incident MI, stroke, peripheral arterial
disease, and sudden cardiac death in multiple prospective epi-
demiological studies,84 and it predicts risk of both recurrent
ischemia and death among those with stable and unstable angina,
those undergoing percutaneous angioplasty, and those pres-
enting to emergency departments with ACS. CRP is not the only
inflammatory biomarker that has been shown to predict MI and
stroke; however, other markers have less clinical utility because
the assays required for their assessment are either inappropriate
for routine clinical use or the protein of interest has too short a
half-life for clinical evaluation.85 In contrast, CRP is highly
stable, allowing accurate measures in both fresh and frozen
plasma without requirements for special collection procedures,
and high-sensitivity assays have been standardized across many
commercial platforms.85 Thus, CRP is an attractive screening
tool for systemic inflammation in patients with PD, although it is
not specific for that disorder.
Helfand et al262 performed a systematic review of risk factors
and surrogate markers with the potential to improve global risk
assessment for CHD, including CRP, CAC score as measured by
electron-beam computed tomography, lipoprotein(a) level, ho-
mocysteine level, leukocyte count, fasting blood glucose, PD,
ankle-brachial index, and cIMT. Good-quality studies relevant to
the prediction of major CHD events using indices of PD,
ankle-brachial index, or cIMT were sparse, so that data were
insufficient for estimating pooled risk ratios for major CHD
events. PD was deemed an independent, although relatively
weak, risk factor for CHD. The authors did not find any direct
evidence that periodontal examination would be useful for
reclassifying people identified as at intermediate risk by the
Framingham risk score. CRP was the best candidate for use in
screening and the most rigorously studied, but evidence that
changes in CRP level lead to primary prevention of CHD events
was inconclusive.262 In another study, Willershausen et al263
found that patients with acute MI exhibited an unfavorable dental
state of health after statistical adjustment for age, sex, and smoking.
That study did not find a significant correlation between CRP and
the number of dental apical lesions on radiography.263
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Association of Periodontitis With ECG Abnormalities
Abnormal ECG findings are often nonspecific and may be
associated with atherosclerotic and nonatherosclerotic cardiac
diseases, including hypertensive, valvular, and infiltrative
disorders. Studies of prevalence of ECG changes in octoge-
narians, Pima Indians, and a Japanese population have sug-
gested that the risk for ECG abnormalities increases with the
severity of PD.199,264,265 In a different Japanese cohort study, no
correlation between PD and prevalence of electrocardiographic
abnormalities was found.266 Thus, the independent correlation of
ECG findings with PD has not been definitively proven.
Periodontal Intervention and ASVD Risk
Whether or not treatment of PD modifies the risk for or
complications of ASVD has yet to be established. The majority
of studies published have examined the effects of different forms
of periodontal therapy on markers of systemic inflammation or
on surrogate markers of subclinical ASVD.
Periodontal therapy consists of mechanical debridement of
root surfaces accompanied by home-based plaque control (tooth
brushing and flossing). Mechanical debridement can be per-
formed nonsurgically or in combination with gingival flap
elevation (surgical periodontal therapy). Supragingival debride-
ment, which does not constitute full periodontal therapy, has
been used as a control treatment in some studies.
Several cohort studies and randomized clinical trials have
reported improvements in endothelial function and associated
markers of inflammation among subjects with significant PD
who have undergone nonsurgical periodontal therapy, with or
without systemic antibiotics,181–183,267,268 which supports the
theory that if cardiovascular toxicity from PD occurs, it is
mediated at least in part through inflammation and endothelial
dysfunction.181–183,267
Recently, a randomized controlled trial involving full-mouth
mechanical debridement by either surgical or nonsurgical ap-
proaches, dictated by the patient’s condition, completed within a
single session and accompanied by extensive application of local
antibiotics in all deep periodontal pockets demonstrated a sig-
nificant improvement in brachial artery FMD at a 6-month
follow-up examination.261 Notably, this intense intervention
resulted in a transient deterioration of FMD and a significant
increase in multiple plasma inflammatory mediators immedi-
ately after debridement, which supports the notion that bacterial
inoculation and other procedure-related inflammation resulting
from mechanical debridement has immediate negative effects on
endothelial function. In another study based on the US Medicaid
claims database, investigators found a transient increased risk for
MI and stroke within the first 4 weeks after invasive dental
procedures (including periodontal therapy or dental surgery);
risk returned to baseline over the subsequent 12 to 24 weeks
after treatment.269
A review of intervention studies that investigated the
effects of periodontal therapy on plasma levels of inflamma-
tory mediators revealed inconsistent findings. Patients treated
by nonsurgical periodontal therapy displayed a significant
increase in plasma tumor necrosis factor-, CRP, and IL-6
levels immediately after intervention, which suggests a sys-
temic acute-phase response, possibly caused by massive
bacterial inoculation in conjunction with instrumentation of
periodontal tissues.267,270–272 Two smaller studies,273,274 1
with surgical and 1 with nonsurgical periodontal therapy
followed by a short course of systemic antibiotics, reported
no significant changes in serum levels of CRP, IL-6, or tumor
necrosis factor- 3 months after therapy. In contrast, in a
6-month posttreatment follow-up of subjects enrolled in a
single-arm intervention study involving nonsurgical peri-
odontal therapy,275 significant reductions in serum IL-6 (me-
dian, decrease 0.2 ng/L; 95% confidence interval, 0.1–0.4
ng/L) and CRP (median decrease, 0.5 mg/L; 95% confidence
interval, 0.4–0.7 mg/L) were demonstrated. A subsequent
randomized controlled pilot trial by the same investigators
compared nonsurgical periodontal therapy alone versus iden-
tical therapy supplemented by local adjunctive minocycline
application276 and found statistically significant reductions in
serum CRP and IL-6 in both treatment arms, as well as a
significant reduction in total and low-density lipoprotein choles-
terol in the group that received adjunctive local antibiotic. Yet in
a larger randomized controlled trial by the same research
group,267 no significant differences posttreatment were reported
in plasma levels of CRP, IL-6, and plasminogen activator
inhibitor-1 between the treatment and control groups at 6
months. The treatment group had a reduction in serum soluble
E-selectin concentration and neutrophil counts.
The most recent available systematic review of 6 treatment
studies investigating the effects of periodontal therapy on
serum CRP levels277 concluded that there is modest evidence
of a treatment-induced reduction in CRP (weighted mean
difference of reductions of 0.50 mg/L; 95% confidence
interval, 0.08–0.93 mg/L). Substantial heterogeneity in short-
term responses in inflammatory markers after surgical peri-
odontal therapy has been shown in a single-arm intervention
study of 19 biomarkers in patients with moderate to severe
periodontitis.278 In that study, approximately one third of
treated patients showed a marked reduction in systemic
inflammation, one fourth showed a pronounced increase in
systemic inflammation, and the remaining patients had no
change. Treatment resulted in discernible changes in the tran-
scriptome gene expression of peripheral blood monocytes, no-
tably in several genes related to innate immunity, apoptosis, and
cell signaling, in a manner compatible with the promotion of an
antiatherogenic phenotype.279 A recent pilot study indicated that
nonsurgical treatment of mild to moderate periodontitis in
otherwise healthy individuals may significantly reduce cIMT at
12 months after completion of treatment.280
To date, only a single multicenter pilot study has examined
the effects of periodontal therapy on the secondary prevention
of cardiac events. The Periodontitis and Vascular Events
(PAVE) investigation281,282 randomized patients with perio-
dontitis and a history of CHD (angiographically proven
coronary artery disease or recent MI or surgical or percuta-
neous coronary revascularization) to either community care
(generally consisting of supragingival debridement only;
control group) or a study protocol that consisted of oral
hygiene instruction and nonsurgical periodontal therapy.
Over a 25-month follow-up period, adverse cardiovascular
events occurred with similar frequency in the community and
the periodontal treatment groups. Periodontal therapy resulted
in limited improvement of periodontal status at 6 months after
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the intervention, but this was not sustainable at 1-year
follow-up. A substantial proportion of individuals random-
ized to the community care group received some form of
preventive or periodontal care outside the study, which
complicates interpretation of the study’s findings. Lastly,
obesity appeared to nullify periodontal treatment effects on a
reduction in serum CRP levels. Important lessons were learned
by this pilot trial that will likely impact the design of future
randomized controlled trials. This includes the requirement for
sustained efforts in periodontal intervention to obtain clinically
and biologically meaningful positive effects on periodontal
status and an appreciation for the role of associated ASVD risk
factors that might alter the impact of a treatment-induced
improvement in systemic inflammation.
Evidence for PD as a Risk Factor for ASVD
The potential associations between PD and ASVD can be
considered in light of published standards for levels of evidence
that include Level of Evidence A, for which supportive data are
derived from multiple randomized clinical trials or meta-analy-
ses, and Level of Evidence B, for which data derive from a
single randomized trial or nonrandomized studies. An associa-
tion between PD and ASVD is supported by evidence that meets
standards for Level of Evidence A. A benefit of periodontal
intervention in decreasing local periodontal inflammation is also
supported by level A evidence. Causation of ASVD by PD is not
supported by either level A or level B evidence. The same is true
about a benefit of periodontal intervention in decreasing long-
term systemic inflammation.
Summary Assessment of the Literature
The relation between PD and ASVD is potentially of great
public health importance because of their high prevalence.
Extensive review of the literature indicates that PD is asso-
ciated with ASVD independent of known confounders. This
information comes mostly from observational studies, how-
ever, and therefore does not demonstrate that PD is a cause of
ASVD, nor does it confirm the contention that therapeutic
periodontal interventions prevent heart disease or stroke or
modify the clinical course of ASVD. Although a contribution
of PD to ASVD is biologically plausible, periodontal and
cardiovascular diseases share multiple risk factors that are
prevalent and powerful promoters of disease, including to-
bacco use, diabetes mellitus, and age.
The role of tobacco use in the observed association between
PD and ASVD outcomes is a critical one, because smoking is a
major risk factor for both conditions, and smoking cessation is a
critical component of health maintenance and prevention of
many diseases, including both PD and ASVD. Recent evidence
indicates that the observed association between PD and ASVD is
independent of smoking, because it has been shown retrospec-
tively and longitudinally that PD and ASVD are associated both
in smokers and in never-smokers.
Available data indicate a general trend toward a periodon-
tal treatment–induced suppression of systemic inflammation
and improvement of noninvasive markers of ASVD and
endothelial function. The effects of PD therapy on specific
inflammatory markers are not consistent across studies, and
their sustainability over time has not been established con-
vincingly, however, and determinants of variability in these
responses remain poorly understood. In addition, transient
proinflammation and deranged endothelial functions are ob-
served after intensive therapy for PD.
This review highlights significant gaps in our scientific
understanding of the interaction of oral health and ASVD.
Identification of clinically relevant aspects of their associa-
tion or therapeutic strategies that might improve the recogni-
tion or therapy of ASVD in patients with PD would require
further study in well-designed controlled interventional stud-
ies. Such investigations should reflect the longitudinal effec-
tiveness of different approaches to managing periodontal
health, given the possibility of PD recurrence after therapy
and the extended time course of evolution of ASVD and its
manifestations. Uniform criteria for PD case definition, ex-
tent, and severity; standardized treatment protocols; and
consideration of time course, important confounders, and
effect modifiers on the association of PD and ASVD would
also improve future studies. Finally, the implications of the
observed transient detrimental effects of PD therapy on
markers of inflammation and endothelial function should be
clarified. In the meantime, statements that imply a causative
association between PD and specific ASVD events or claim
that therapeutic interventions may be useful on the basis of
that assumption are unwarranted.
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Abbreviations List
ABI Ankle-brachial index
ACS Acute coronary syndrome
ASVD Atherosclerotic vascular disease
BANA Benzoyl-DL-arginine naphthylamide
CAC Coronary artery calcium
CHD Coronary heart disease
cIMT Carotid intima-media thickness
CRP C-reactive protein
CVA Cerebral vascular accident
FMD Flow-mediated vasodilation
HR Hazard ratio
HSP Heat shock protein
IL Interleukin
MI Myocardial infarction
OR Odds ratio
PD Periodontal disease
RR Relative Risk
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